Research ArticleClinical Studies

Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer

SHINICHI TATE, KYOKO NISHIKIMI, AYUMU MATSUOKA, SATOYO OTSUKA and MAKIO SHOZU
Anticancer Research May 2022, 42 (5) 2637-2644; DOI: https://doi.org/10.21873/anticanres.15741

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Study protocol comparing treatment periods for brain metastasis. In total, 21 patients received whole-brain radiation therapy or gamma knife radiosurgery. Five patients received craniotomy due to larger and symptomatic metastasis. #Two patients received palliative therapy for brain metastasis due to poor performance status.

  • Figure 2.
    Figure 2.

    Survival after brain metastasis. The median survival was 9.1 months in this study.

  • Figure 3.
    Figure 3.

    Survival after brain metastasis between the former and latter periods. The median survival during the former and latter periods was 2.9 and 33.5 months, respectively.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer
SHINICHI TATE, KYOKO NISHIKIMI, AYUMU MATSUOKA, SATOYO OTSUKA, MAKIO SHOZU
Anticancer Research May 2022, 42 (5) 2637-2644; DOI: 10.21873/anticanres.15741
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords